Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):651-9. doi: 10.1016/j.ijrobp.2006.09.035. Epub 2006 Dec 15.

Abstract

Purpose: The aim of this study was to compare changes in salivary gland function after intensity-modulated radiotherapy (IMRT) and conventional radiotherapy (RT), with or without Amifostine, for tumors of the head-and-neck region using quantitative salivary gland scintigraphy (QSGS).

Methods and materials: A total of 75 patients received pre- and post-therapeutic QSGS to quantify the salivary gland function. In all, 251 salivary glands were independently evaluated. Changes in the maximum uptake (DeltaU) and relative excretion rate (DeltaF) both pre- and post-RT were determined to characterize radiation-induced changes in the salivary gland function. In addition, dose-response curves were calculated.

Results: In all groups, maximum uptake and relative excretion rate were reduced after RT (DeltaU <or=0 and DeltaF <or=0). The reduction was significantly lower for IMRT than for conventional RT. For the parotid glands, the reduction was smaller for the IMRT-low than for the IMRT-high group. For the Amifostine-high and the conventional group the difference was significant only for one parameter (DeltaU, parotid and submandibular glands, p < 0.05). In contrast to this, the difference between the Amifostine-low and the conventional group was always significant or at least showed a clear trend for both changes in U and F. In regard to the endpoint "reduction of the salivary gland excretion rate of more than 50%," the dose-response curves yielded D50-values of 34.2 +/- 12.2 Gy for the conventionally treated group and 36.8 +/- 2.9 Gy for the IMRT group. For the Amifostine group, an increased D50-values of 46.3 +/- 2.3 Gy was obtained.

Conclusion: Intensity-modulated RT can significantly reduce the loss of parotid gland function when respecting a certain dose threshold. Conventional RT plus Amifostine prevents reduced salivary gland function only in the patient group treated with <40.6 Gy.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Amifostine / therapeutic use
  • Dose-Response Relationship, Radiation
  • Female
  • Head and Neck Neoplasms / radiotherapy*
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Parotid Gland / diagnostic imaging
  • Parotid Gland / radiation effects
  • Radiation-Protective Agents / therapeutic use
  • Radionuclide Imaging
  • Radiopharmaceuticals*
  • Radiotherapy, Intensity-Modulated / adverse effects*
  • Salivary Glands / diagnostic imaging
  • Salivary Glands / radiation effects*
  • Salivation / radiation effects
  • Sodium Pertechnetate Tc 99m*
  • Xerostomia / diagnostic imaging
  • Xerostomia / etiology

Substances

  • Radiation-Protective Agents
  • Radiopharmaceuticals
  • Sodium Pertechnetate Tc 99m
  • Amifostine